# US 2021/0171580 A1 · Thermostable viral reverse transcriptase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171580 A1
- Document ID: US20210171580A1
- Status: Published application
- Kind: A1
- Application number: 17/052,237
- Filed: 2019-04-30
- Published: 2021-06-10
- Earliest claimed: 2018-05-02
- Assignees: Qiagen Beverly, LLC.
- Applicants: Qiagen Beverly, LLC.
- Inventors: Thomas William Schoenfeld; Ryan Charles Heller; Katarzyna Crissy; Suhman Chung
- Web page: https://patentgrep.com/patent/US20210171580A1

## CPC

- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/005: from viruses
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12Q 1/6844: Nucleic acid amplification reactions
- C12N 2795/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12Q 2531/113: PCR
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides novel engineered polypeptides that support both reverse transcription and DNA amplification in manganese-independent reactions. The present invention also provides methods for amplifying template nucleic acids using such polypeptides. This invention addresses deficiencies in the current state of the art in nucleic acid amplification-based detection of template nucleic acids, especially RNA targets, including deficiencies in detection sensitivity, specificity, enzyme stability, inhibitor tolerance and time to result compared with manganese-dependent thermostable reverse transcriptases and two-enzyme solutions.

## Claims

### Claim 1

A polypeptide comprising a polymerase domain comprising an amino acid sequence of SEQ ID NO:16 and an amino acid sequence selected from the group consisting of SEQ ID NO:17 and SEQ ID NO:72, or amino acid sequences at least 90%, preferably at least 95%, more preferably at least 98% identical thereto.

### Claim 2 (depends on 1)

The polypeptide according to claim 1, wherein the N-terminus of the polymerase domain corresponds to the sequence of positions 12-22 of the sequence of SEQ ID NO:15, or a sequence at least 90%, preferably at least 95%, more preferably at least 98% identical thereto.

### Claim 3 (depends on 2)

The polypeptide according to claim 2, wherein the N-terminus is an amino acid sequence of “MN(X1)PKPILKPQ(X2)KALVEPVLC(X3)SI(X4)EIPA” (SEQ ID NO:21); or variants thereof, wherein X1=A or T; X2═P or S; X3═N or D; and X4═N or D.

### Claim 4 (depends on 1)

The polypeptide according to claim 1, wherein the polymerase domain comprises an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12, or an amino acid sequence at least 90%, preferably at least 95%, more preferably at least 98% identical thereto.

### Claim 5 (depends on 1)

A polypeptide according to claim 1, further comprising an exonuclease domain connected to the polymerase domain, preferably via a linker.

### Claim 6 (depends on 5)

The polypeptide according to claim 5, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:14, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80 or an amino acid sequence at least 90%, preferably at least 95%, more preferably at least 98% identical thereto.

### Claim 7 (depends on 1)

The polypeptide according to claim 1, wherein the polypeptide exhibits reverse transcriptase activity and/or 5′→3′ exonuclease activity.

### Claim 8 (depends on 1)

A composition comprising a polypeptide according to claim 1.

### Claim 9 (depends on 1)

A vector encoding the polypeptide according to claim 1.

### Claim 10 (depends on 8)

A transformed host cell comprising the vector according to claim 8.

### Claim 11 (depends on 1)

A method for amplifying template nucleic acids comprising contacting the template nucleic acids with a polypeptide according to claim 1, preferably wherein the method is reverse transcription (RT) PCR.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the method comprises:
a) generating cDNA using the polypeptide; and
b) amplifying the generated cDNA using the polypeptide.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the same polypeptide is applied for steps a) and b).

### Claim 14 (depends on 12)

The method according to claim 12, wherein reverse transcription of step a) and the amplification of step b) are performed at isothermal conditions.

### Claim 15 (depends on 1)

A kit comprising
a) the polypeptide of claim 1; and
a buffer.
